First, all CM derived from A549 lung cancer cells treated with the three different MAGL inhibitors JZL184, JW651, and MJN110 inhibited the migration and tube formation of HUVECs, thus ruling out an off-target effect of JZL184, which was in the focus of subsequent more detailed mechanistic studies. The gene discussed is MGLL; the disease is lung cancer.